Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...

A GSK pill that offers a lower potential for drug resistance is now FDA approved as a new treatment for a common type of urinary tract infection, the first new oral antibiotic for this indication ...

GSK Price Performance Shares of NYSE:GSK opened at $39.44 on Friday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The business has a 50-day moving average of $36 ...

GSK plans the therapy’s commercial launch in the US for the second half of 2025. Credit: MAXSHOT.PL/Shutterstock. The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene ...

GSK’s mepolizumab programme in chronic obstructive pulmonary disease includes three studies. Credit: HJBC/Shutterstock. The European Medicines Agency (EMA) has agreed to review GSK’s application of ...

Two attorneys from Dechert have entered an appearance for GlaxoSmithKline in a securities class action that alleges the health care giant failed to properly disclose a 1982 report that showed the ...

During Lacalle's meeting with British Prime Minister Boris Johnson, the launch of a sovereign bond linked to sustainability goals was discussed Pharmaceutical giant GlaxoSmithKline (GSK ...